Kuchyne na miru

Latest

Utilizing an Integrated, MultiChannel Approach Can Improve Access for Oncology Products

By McKesson Life Sciences - Brand Insights

How biopharma companies can pursue multiple channels to enhance access to segmented markets.

Proposed Rule to Eliminate Pharmaceutical Rebates Raises Challenging Questions

By Dean Erhardt

A rule to eradicate drug rebates and prompt direct discounts for federal beneficiaries raises challenging questions for drug manufacturers and other stakeholders.

FDA Pushes for “Clear Global Policy Strategy”

By Jill Wechsler

FDA is examining and updating its programs for overseeing global operations and international affairs.

Use of High-Efficacy Therapies in MS

By Simone Gabriele and Elizabeth Baynton

Opinion remains divided regarding how aggressively MS should be treated. Some neurologists believe in the “treat early, treat aggressively” approach, whilst others prefer to “save” HE therapies until the more traditional platform therapies have failed.

Pharm Exec Video

A Conversation with Paul Jones, Director, Population Genomics, Illumina

Paul Jones, Director, Population Genomics, Illumina talks with Pharm Exec's European Editor, Julian Upton, at the 2019 17th Annual Patient Engagement eyeforpharma Barcelona event about population genomics.

A Conversation with Kris Sterkens, Group Chairman, EMEA, Janssen

Kris Sterkens, Group Chairman, EMEA, Janssen speaks with Pharm Exec's European Editor, Julian Upton at the 2019 17th Annual Patient Engagement eyeforpharma Barcelona event.

A Conversation with Kabir Nath, President & CEO, Otsuka North America

Pharm Exec's European Editor, Julian Upton, interviews Kabir Nath, President & CEO, Otsuka North America, at the 2019 17th Annual Patient Engagement eyeforpharma Barcelona event to discuss digital therapeutics.

New & Noteworthy

Impact Investing and R&D

Exploring the rise of environmental, social, and governance investing and venture philanthropy in accelerating drug development.

The Role of Commercial Partners in Sales Strategy Development

Greg Flynn discusses the advantages, challenges and possible future of CCOs and outlines their role in effective sales strategy development.

FDA After Gottlieb: Thorny Issues, Political Challenges

New leadership faces a host of complex initiatives to promote innovation and protect public health. Jill Wechsler reports.

Building the Startup Dream Team

Chris Coe argues that start-ups should build their teams early and put depth of business experience before all else.

Skills Shortage: An Imminent Threat to Life Sciences Innovation

Industry needs to realize the potential that new treatments and technologies hold and put skills at the top of its collective agenda, write Ian Marison and Peter Levison.

From the Editor

We’ve Got You Covered

With conference season in high gear, here's the lowdown on our content highlights so far from the event circuit and what to expect on horizon.

Sharing Your Voice

The lifeblood of our coverage are the many interviews we conduct with industry executives—and the unique stories and insights they provide. Here, I highlight excerpts from a selection of wide-ranging conversations from the past year.

eBooks

Emerging BioPharma: Your Guide to Clinical and Commercial Considerations

This eBook will focus on the specific needs and concerns of the smaller to mid-size biopharmaceutical company. Articles cover considerations from Phase II to commercial pathways. 

View all eBooks

PEspeaks

Clearing Up ‘Clear Evidence’ and Implications for Labeling Post-Merck Decision

Intellectual property attorneys discuss the clarified requirements for when state failure-to-warn claims are pre-empted by FDA regulations after the Supreme Court Merck case.

The eyeforpharma Awards 2019: Nominations OPEN NOW

Nominations for the 2019 eyeforpharma awards are currently open.

We’ve Got You Covered

With conference season in high gear, here's the lowdown on our content highlights so far from the event circuit and what to expect on horizon.

Adopting New Technology: Barriers and Breakthroughs

Chrissy Bell on preserving positive ROI amid healthcare’s innovation explosion.

Interviews

A Common Vision for Finance

Mundipharma CFO Arnaud Breabout talks about how he has seen the CFO role evolve over his 20-plus years in the life sciences industry.

Evolving with Esperion: CFO Rick Bartram

Esperion CFO Rick Bartram highlights his involvement in the young organization's success over the last six years and discusses what the company mission means to him.

Patient Centricity by Prodrug Design

Travis Mickle, CEO of KemPharm, talks about his company’s use of prodrugs, the business opportunities prodrugs represent, and how prodrugs are helping to improve patient centricity.

Planning Ahead with AstraZeneca's Pam Cheng

A discussion with Pam Cheng, executive vice president of Operations, Technology at AstraZeneca about making the transition into a Fortune 500 C-Suite role and leadership advice for success.

Biopharma Tackles Antimicrobial-Resistant Fungi

SCYNEXIS CEO, Marco Taglietti, talks about efforts to help advance fungal disease treatments.

One CEO, Two Pharma Companies

Hugh McTavish, CEO of Squarex and IGF-Oncology, shares his perspectives on running both enterprises and the medical products each is developing.

Regulatory

FDA Pushes for “Clear Global Policy Strategy”

FDA is examining and updating its programs for overseeing global operations and international affairs.

FDA After Gottlieb: Thorny Issues, Political Challenges

New leadership faces a host of complex initiatives to promote innovation and protect public health. Jill Wechsler reports.

The Great Life Sciences Regulatory Redress

Elvis Paćelat outlines some lessons from big pharma as medical device manufacturers succumb to new reporting obligations.

Sharpless Outlines Priorities for Overseeing FDA’s “Huge Portfolio”

New FDA leader Ned Sharpless will seek further solutions to the opioid crisis and work to reduce cigarette use in adults and kids.

piratecodex.us

http://profvest.com

читайте здесь www.profvest.com
lorem ipsum